Risk of xerostomia in association with the receipt of radiation therapy in older patients with head and neck cancer

American Journal of Therapeutics

Volumn 18, Issue 3, 2011, Pages 206-215

  Liu, Chih Chin ^a   Xia, Rui ^a   Guadagnolo, Ashleigh ^b   Cormier, Janice N ^b   Du, Xianglin L ^a,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

head and neck cancer; incidence; Medicare; radiation therapy; xerostomia

Indexed keywords

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GERIATRIC DISORDER; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION INJURY; RISK ASSESSMENT; XEROSTOMIA;

AGED; AGED, 80 AND OVER; AMIFOSTINE; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; NEOPLASM STAGING; RADIATION-PROTECTIVE AGENTS; REGISTRIES; RISK; TIME FACTORS; XEROSTOMIA;

EID: 79958057214     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181c960dc     Document Type: Article

References (47)

1. Adami HO, Hunter D, Trichopoulos D. Textbook of Cancer Epidemiology. New York, NY: Oxford University Press; 2002.
2. Abraham J, Allegra CJ. Bethesda Handbook of Clinical Oncology. Philadelphia, PA: LippincottWilliams &Wilkins; 2001.
3. National Cancer Institute. SEER Stat Fact Sheets. Available at: http://seer.cancer.gov/statfacts/html/oralcav.html. Accessed June 5, 2009.
4. American Cancer Society. Cancer Facts & Figures 2009. Atlanta, GA: American Cancer Society; 2009. Available at: http://www.cancer.org/downloads/ STT/500809web.pdf. Accessed June 9, 2009.
5. Salama JK, Haddad RI, Kies MS, et al. Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;75:725-733.
6. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945-1952. (Pubitemid 38580197)
7. Chambers MS, Garden AS, Kies MS, et al. Radiationinduced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. Head Neck. 2004;26:796-807. (Pubitemid 39159303)
8. Dirix P, Nuyts S, Van den Bogaert W. Radiation-induced xerostomia in patients with head and neck cancer: a literature review. Cancer. 2006;107:2525-2534. (Pubitemid 44845604)
9. Chambers MS, Rosenthal DI, Weber RS. Radiationinduced xerostomia. Head Neck. 2007;29:58-63.
10. Citrin D, Mansueti J, Likhacheva A, et al. Long-term outcomes and toxicity of concurrent paclitaxel and radiotherapy for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;74:1040-1046.
11. Semenenko VA, Li XA. Lyman-Kutcher-Burman NTCP model parameters for radiation pneumonitis and xerostomia based on combined analysis of published clinical data. Phys Med Biol. 2008;53:737-755. (Pubitemid 351496215)
12. Chao KS, Deasy JO, Markman J, et al. A prospective study of salivary function sparing in patients with head-andneck cancers receiving intensity-modulated or threedimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys. 2001;49:907-916. (Pubitemid 32184597)
13. Eisbruch A, Ten Haken RK, Kim HM, et al. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol. Biol Phys. 1999; 45:577-587. (Pubitemid 29462636)
14. Roesink JM, Moerland MA, Battermann JJ, et al. Quantitative dose-volume response analysis of changes in parotid gland function after radiotherapy in the headand- neck region. Int J Radiat Oncol Biol Phys. 2001;51: 938-946. (Pubitemid 33026423)
15. Scrimger RA, Stavrev P, Parliament MB, et al. Phenomenologic model describing flow reduction for parotid gland irradiation with intensity-modulated radiotherapy: evidence of significant recovery effect. Int J Radiat Oncol Biol Phys. 2004;60:178-185. (Pubitemid 39165483)
16. Kahn ST, Johnstone PA. Management of xerostomia related to radiotherapy for head and neck cancer. Oncology (Williston Park). 2005;19:1827-1832.
17. Berk LB, Shivnani AT, Small W Jr. Pathophysiology and management of radiation-induced xerostomia. J Support Oncol. 2005;3:191-200. (Pubitemid 40852401)
18. de Castro G Jr, Federico MH. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients. Curr Opin Oncol. 2006;18: 266-270. (Pubitemid 43740422)
19. Hall EJ. Radiobiology for the Radiologist. Chapter 19. Philadelphia, PA: Lippincott Williams and Wilkins; 2000.
20. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, et al. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol. 2008;26:3770-3776.
21. Dirix P, Nuyts S, Vander Poorten V, et al. The influence of xerostomia after radiotherapy on quality of life: results of a questionnaire in head and neck cancer. Support Care Cancer. 2008;16:171-179.
22. Wijers OB, Levendag PC, Braaksma MM, et al. Patients with head and neck cancer cured by radiation therapy: a survey of the dry mouth syndrome in long-term survivors. Head Neck. 2002;24:737-747. (Pubitemid 34857299)
23. Amosson CM, Teh BS, Mai WY, et al. Using technology to decrease xerostomia for head and neck cancer patients treated with radiation therapy. Semin Oncol. 2002;29 (6 Suppl 19):71-79. (Pubitemid 36173252)
24. Koukourakis MI, Danielidis V. Preventing radiation induced xerostomia. Cancer Treat Rev. 2005;31:546-554. (Pubitemid 41614812)
25. Schiff E, Mogilner JG, Sella E, et al. Hypnosis for postradiation xerostomia in head and neck cancer patients: a pilot study. J Pain Symptom Manage. 2009;37:1089- 1092.e1.
26. Amosson CM, Teh BS, Van TJ, et al. Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique. Int J Radiat Oncol Biol Phys. 2003;56:136-144. (Pubitemid 36403685)
27. Chambers MS, Garden AS, Rosenthal D, et al. Intensitymodulated radiotherapy: is xerostomia still prevalent? Curr Oncol Rep. 2005;7:131-136. (Pubitemid 40485469)
28. National Cancer Institute. Surveillance Epidemiology and End Results. Available at: http://seer.cancer.gov/index. html. Accessed May 26, 2009.
29. Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked Medicaretumor registry database. Med Care. 1993;31:732-748.
30. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(Suppl 8):IV3-IV18.
31. U.S. Public Health Services. International Classification of Diseases, 9th Revision, Clinical Modification. 5th ed. Los Angeles, CA: Practice Management Information Corporation; 1996.
32. Du XL, Freeman JL, Goodwin JS. Information on radiation treatment in patients with breast cancer: the advantages of the linked Medicare and SEER data. J Clin Epidemiol. 1999;52:463-470. (Pubitemid 29305352)
33. American Medical Association. Physicians' Current Procedural Terminology-CPT 2000. Chicago, IL: American Medical Association; 2000.
34. Health Care Financing Administration. HCFA Common Procedure Coding System: National Level II Medicare Codes. Los Angeles, CA: Practice Management Information Corporation; 2000.
35. Du XL, Goodwin JS. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol. 2001;19:1455-1461. (Pubitemid 32202553)
36. Du XL, Key CR, Dickie L, et al. External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews. Med Care. 2006;44:124-131. (Pubitemid 43755463)
37. Smith GL, Smith BD, Buchholz TA, et al. Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. J Clin Oncol. 2008;26:5119-5125.
38. National Cancer Institute. SEER-Medicare: Calculation of Comorbidity Weights. Available at: http://healthservices. cancer.gov/seermedicare/program/ comorbidity.html. Accessed July 23, 2008.
39. Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267. (Pubitemid 32007842)
40. Du XL, Chan W, Giordano S, et al. Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity. Cancer. 2005;104:913-924. (Pubitemid 41170217)
41. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40: 373-383. (Pubitemid 17055592)
42. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
43. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46: 1075-1079.
44. Allison PD. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute Inc; 1995.
45. Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity modulated radiotherapy on salivary gland function in early stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25:4873-4879. (Pubitemid 350220416)
46. Harrison, LB, Zelefsky MJ, Pfister DG, et al. Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of tongue. Head Neck. 1997;19:169-175. (Pubitemid 27185043)
47. Epstein JB, Robertson M, Emerton S, et al. Quality of life and oral function in patients treated with radiation therapy for head and neck cancer. Head Neck. 2001;23: 389-398.